Neumora Therapeutics (NMRA) Operating Leases (2022 - 2026)

Neumora Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $119000.0 for Q1 2026.

• In Q1 2026, Operating Leases changed N/A year-over-year to $119000.0; the TTM figure through Mar 2026 stood at $119000.0 (changed N/A YoY), while the FY2025 annual figure was $193000.0, changed N/A from the prior year.
• Operating Leases for Q1 2026 stood at $119000.0, down from $193000.0 in the prior quarter.
• The five-year high for Operating Leases was $5.1 million in Q4 2022, with the low at $119000.0 in Q1 2026.
• The 5-year median for Operating Leases is $638500.0 (2024), against an average of $1.4 million.
• Peak annual rise in Operating Leases reached 63.47% in 2023, while the deepest fall reached 63.47% in 2023.
• Neumora Therapeutics' Operating Leases stood at $5.1 million in 2022, then slumped by 63.47% to $1.9 million in 2023, then tumbled by 49.38% to $938000.0 in 2024, then slumped by 79.42% to $193000.0 in 2025, then sank by 38.34% to $119000.0 in 2026.
• Business Quant data shows NMRA's Operating Leases at $119000.0 in Q1 2026, $193000.0 in Q4 2025, and $267000.0 in Q3 2025.